v3.25.2
Segment Information
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

Note 10.Segment Information

The Company has one operating segment and, therefore, one reportable segment, which comprises the discovery, development and commercialization of transformative therapies for cardio-metabolic diseases.

To date the Menarini License has been the only source of revenue to the Company and all such revenues derive from Italy.

The chief operating decision maker assesses performance and decides how to allocate resources based on consolidated net loss and earnings/(loss) before tax, adjusted for certain non-cash and non-operating items such as share-based compensation, change in fair value of derivatives and foreign currency gains or losses. Adjusted earnings/(loss) before taxes is used to monitor budget versus actuals and evaluate the operations of the Company. The measure of segment assets is reported on the balance sheet as total consolidated assets. The future prospects of the Company are highly dependent upon the results of its ongoing clinical trials and interactions with regulatory agencies. Such results and interactions are utilized together with assessment of the comparison of budget versus actuals in order to make decisions regarding the allocation of resources.

The following table presents the adjusted loss before taxes for the Company's single segment for each of the three and six months ended June 30, 2025 and 2024:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

(In thousands of USD)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Revenue

 

 

19,145

 

 

 

2,279

 

 

 

22,123

 

 

 

3,680

 

Interest income

 

 

7,055

 

 

 

4,870

 

 

 

14,406

 

 

 

7,953

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Personnel expense

 

 

9,900

 

 

 

7,017

 

 

 

20,063

 

 

 

12,286

 

External R&D expense

 

 

14,577

 

 

 

28,449

 

 

 

43,904

 

 

 

61,053

 

Manufacturing expense

 

 

4,289

 

 

 

4,277

 

 

 

10,130

 

 

 

7,938

 

Regulatory expense

 

 

1,025

 

 

 

408

 

 

 

2,042

 

 

 

900

 

Commercial programs

 

 

5,396

 

 

 

2,750

 

 

 

11,303

 

 

 

6,239

 

General and administrative expense

 

 

4,307

 

 

 

3,597

 

 

 

8,629

 

 

 

7,016

 

Depreciation and amortization

 

 

107

 

 

 

66

 

 

 

220

 

 

 

97

 

Segment adjusted loss before tax

 

 

(13,401

)

 

 

(39,415

)

 

 

(59,762

)

 

 

(83,896

)

Reconciliation to consolidated net loss

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation expense

 

 

(15,179

)

 

 

(8,290

)

 

 

(30,392

)

 

 

(16,208

)

Change in fair value - derivatives

 

 

2,590

 

 

 

9,692

 

 

 

20,344

 

 

 

(29,258

)

Foreign exchange gains/(losses)

 

 

8,626

 

 

 

(994

)

 

 

12,919

 

 

 

(3,412

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated net loss for the period

 

 

(17,364

)

 

 

(39,007

)

 

 

(56,891

)

 

 

(132,774

)